Skip to content

Rich Pharmaceuticals, Inc.: 10-Q filed 2015-11-23

What Rich Pharmaceuticals, Inc. reported in its quarterly report filed 2015-11-23 (fiscal Q2 2015): 23 published measures, 58 facts as tagged in accession 0001647488-15-000179.

This filing

Form
10-Q (quarterly report)
Filed
2015-11-23
Fiscal period
fiscal Q2 2015
Accession
0001647488-15-000179 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Rich Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2015-09-302,645USD
At 2015-03-3124,258USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2015-09-301,911,985USD
At 2015-03-311,743,199USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2015-09-30-1,909,340USD
At 2015-03-31-1,718,941USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2015-03-3115,892USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2015-07-01 to 2015-09-30-309,224USD92
2015-04-01 to 2015-09-30-956,967USD183
2014-07-01 to 2014-09-30-670,899USD92
2014-04-01 to 2014-09-30-1,191,356USD183

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2015-04-01 to 2015-09-30-231,136USD183
2014-04-01 to 2014-09-30-750,047USD183

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2015-04-01 to 2015-09-30215,244USD183
2014-04-01 to 2014-09-30741,500USD183

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2015-09-30-8,391,947USD
At 2015-03-31-7,434,980USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2015-09-30552USD
At 2015-03-31788USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2015-07-01 to 2015-09-3062,301USD92
2015-04-01 to 2015-09-30192,392USD183
2014-07-01 to 2014-09-3061,149USD92
2014-04-01 to 2014-09-30181,441USD183

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2015-07-01 to 2015-09-30-234,528USD92
2015-04-01 to 2015-09-30-560,442USD183
2014-07-01 to 2014-09-30-517,827USD92
2014-04-01 to 2014-09-30-1,036,035USD183

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2015-09-302,093USD
At 2015-03-3123,470USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2015-07-01 to 2015-09-30-11,082USD92
2015-04-01 to 2015-09-30-20,255USD183
2014-07-01 to 2014-09-30-7,680USD92
2014-04-01 to 2014-09-30-9,929USD183

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2015-09-301,876,308USD
At 2015-03-311,659,344USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2015-09-30910,803USD
At 2015-03-31910,272USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2015-07-01 to 2015-09-30234,528USD92
2015-04-01 to 2015-09-30560,442USD183
2014-07-01 to 2014-09-30517,827USD92
2014-04-01 to 2014-09-301,036,035USD183

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2015-07-01 to 2015-09-302,000USD92
2015-04-01 to 2015-09-309,000USD183

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2015-09-302,404,530USD
At 2015-03-314,168,956USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2015-09-30338,289USD
At 2015-03-31200,891USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2015-09-302,093USD
At 2015-03-317,578USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2015-09-300USD
At 2015-03-310USD

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2015-07-01 to 2015-09-30118USD92
2015-04-01 to 2015-09-30236USD183
2014-04-01 to 2015-03-31473USD365
2014-07-01 to 2014-09-30118USD92
2014-04-01 to 2014-09-30236USD183

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2015-04-01 to 2015-09-30531USD183
2014-04-01 to 2014-09-30-10,583USD183

Inspect the source

Entity
Rich Pharmaceuticals, Inc. / CIK 0001504389
Captured
SEC response SHA-256
915b548928758b0cd7825b62d7fc36ff2ecd50f0e88985055b0b19ae94428b67

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001504389.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))